{"id":"utidelone-plus-metronomic-capecitabine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Utidelone is a topoisomerase inhibitor that binds to the topoisomerase II-DNA complex, preventing DNA replication. Metronomic capecitabine, on the other hand, is a prodrug that is converted into 5-fluorouracil, which is then converted into 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), a potent inhibitor of thymidylate synthase. This inhibition leads to the depletion of thymidine, a nucleotide required for DNA synthesis, thereby inhibiting cancer cell growth.","oneSentence":"Utidelone is a chemotherapy medication that works by interfering with DNA replication, while metronomic capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:43.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05172518","phase":"PHASE3","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-03-01","conditions":"Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Utidelone plus Metronomic Capecitabine","genericName":"Utidelone plus Metronomic Capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Utidelone is a chemotherapy medication that works by interfering with DNA replication, while metronomic capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase. Used for Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}